Ubs Group Ag Enlivex Therapeutics Ltd. Transaction History

Ubs Group Ag

$400 Billion
Q2 2024

A detailed history of Ubs Group Ag transactions in Enlivex Therapeutics Ltd. stock. As of the latest transaction made, Ubs Group Ag holds 16 shares of ENLV stock, worth $20. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 3,069 99.48%

Holding current value

$20

Previous $11,000 100.0%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$1.27 - $4.31 $3,877 - $13,158	-3,053 Reduced 99.48%	16 $0
Q1 2024 May 13, 2024	SELL	$2.54 - $4.3 $1,508 - $2,554	-594 Reduced 16.22%	3,069 $11,000
Q4 2023 Feb 09, 2024	BUY	$1.29 - $2.92 $3,835 - $8,681	2,973 Added 430.87%	3,663 $9,000
Q3 2023 Nov 09, 2023	SELL	$1.46 - $2.97 $24,995 - $50,846	-17,120 Reduced 96.13%	690 $1,000
Q2 2023 Aug 11, 2023	SELL	$2.51 - $3.71 $34,243 - $50,615	-13,643 Reduced 43.38%	17,810 $46,000
Q1 2023 May 12, 2023	SELL	$3.41 - $4.55 $6,792 - $9,063	-1,992 Reduced 5.96%	31,453 $114,000
Q4 2022 Feb 08, 2023	BUY	$3.74 - $4.81 $5,886 - $7,570	1,574 Added 4.94%	33,445 $131,000
Q3 2022 Nov 10, 2022	BUY	$4.11 - $5.87 $55,443 - $79,186	13,490 Added 73.39%	31,871 $136,000
Q2 2022 Aug 10, 2022	BUY	$3.81 - $8.64 $2,659 - $6,030	698 Added 3.95%	18,381 $83,000
Q1 2022 May 16, 2022	SELL	$4.92 - $6.66 $19,497 - $26,393	-3,963 Reduced 18.31%	17,683 $99,000
Q4 2021 Feb 14, 2022	BUY	$5.81 - $9.73 $35,975 - $60,248	6,192 Added 40.07%	21,646 $135,000
Q3 2021 Nov 15, 2021	BUY	$7.43 - $13.86 $15,112 - $28,191	2,034 Added 15.16%	15,454 $152,000
Q2 2021 Aug 13, 2021	BUY	$8.61 - $12.1 $21,938 - $30,830	2,548 Added 23.44%	13,420 $120,000
Q1 2021 May 12, 2021	SELL	$9.26 - $24.0 $106,740 - $276,648	-11,527 Reduced 51.46%	10,872 $120,000
Q4 2020 Feb 11, 2021	BUY	$8.16 - $14.5 $99,299 - $176,450	12,169 Added 118.95%	22,399 $189,000
Q3 2020 Nov 12, 2020	BUY	$4.64 - $5.94 $45,871 - $58,722	9,886 Added 2873.84%	10,230 $61,000
Q2 2020 Jul 31, 2020	BUY	$4.4 - $6.4 $1,513 - $2,201	344 New	344 $2,000
Q1 2020 May 01, 2020	SELL	$3.77 - $9.91 $10,831 - $28,471	-2,873 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$6.61 - $27.48 $2,035 - $8,463	-308 Reduced 9.68%	2,873 $24,000
Q3 2019 Nov 14, 2019	BUY	$19.7 - $39.42 $32,327 - $64,688	1,641 Added 106.56%	3,181 $85,000
Q2 2019 Aug 14, 2019	BUY	$8.32 - $21.5 $12,812 - $33,110	1,540 New	1,540 $33,000

Others Institutions Holding ENLV

# of Institutions

Shares Held

2.1M

Call Options Held

16.1K

Put Options Held

3.4K

View Full List

About Enlivex Therapeutics Ltd.

Ticker ENLV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,403,200
Market Cap $23.4M
Description
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...

More about ENLV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account